In order to support several client programs in this exciting, rapidly developing area, we have established a suite of value-adding in vitro assays, which together with our knowledge of IO discovery enables you to efficiently navigate this complex area of biology to support the identification of novel targets and the development of a deeper understanding of your compounds mode of action.
At Sygnature Discovery we offer a range of research tools to study the processes involved in immuno-oncology, including the assessment of cytokines, intracellular signalling, T-cell proliferation assays and antibody-dependent cell cytotoxicity (ADCC) assays.
This platform provides clients with an opportunity to rapidly screen compound collections or biologics to identify candidates that impact particular aspects of immune cell function, as well as providing a cost-effective means to fully explore the mechanism of action prior to more time-consuming in vivo animal studies. Key aspects of this platform include ready access to freshly isolated whole blood; via our in-house Blood Donor Panel, isolation and culturing of distinct immune cell populations and a range of established immuno-oncology assays, in addition to interactions with experienced scientists adept at developing bespoke assays. This platform is fully supported by expert Chemistry, DMPK, Computational Chemistry capabilities.
Platform Highlights include:
- In-House Blood Donor Panel
- Immune cell isolation
- Multiplex Flow Cytometry
- Cytokine release assays
- T-cell proliferation/clustering Assays
- Immune Cell Mediated Killing Assays
- Antibody-dependent cell cytotoxicity (ADCC)
- Phagocytosis (ADCP)
- Monocyte differentiation
- Checkpoint Inhibitor Assays
- Mixed Lymphocyte Reaction (MLR)